Bumetanide Injection · #10 of 35 active shortages by FDA posting duration
Brand: BUMETANIDE
FDA lists Bumetanide Injection as Active Shortage (Sagent Pharmaceuticals).
Availability on file: Limited Availability
Bumetanide Injection: Active Shortage
Limited Availability 17 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Bumetanide Injection
- Manufacturer
- Sagent Pharmaceuticals
- Dosage Form
- Injection
- Presentation
- Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)
- Package NDC
- 25021-321-10
Status & Timeline
- Status
- Active Shortage
- Availability
- Limited Availability
- First Reported
- Jan 31, 2018
- Last Updated
- Mar 3, 2026
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Estimated limited availablilty until April 2026
Full Drug Profile
bumetanide
Side effects, interactions, warnings & more
Nearby, Other Bumetanide Shortage Records
Bumetanide Injection
Fresenius Kabi USA, LLC
Injection
Bumetanide Injection
Fresenius Kabi USA, LLC
Injection
Bumetanide Injection
Mullan Pharmaceutical Inc.
Injection
Bumetanide Injection
Mullan Pharmaceutical Inc.
Injection
Bumetanide Injection
Hikma Pharmaceuticals USA, Inc.
Injection
Bumetanide Injection
Hikma Pharmaceuticals USA, Inc.
Injection
FDA reason on file: Estimated limited availablilty until April 2026. General shortage guidance lives on the tracker hub.